The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2

To date, studies on anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine efficacy in blood cancers show that different responses may be observed according to the haematological malignancy diagnosis, stage of disease and ongoing treatment. Immune responses are often lower compared to healthy controls, second doses appear to be crucial, and most of the evidence rely on tests of neutralising antibody response, not the full range of immune response or clinical outcomes.1–10 We do not know how long immunity lasts in such patients, and there is uncertainty about the most reliable serological tests and cut-off values by which to identify the responders and track the putatively neutralising antibodies’ titres.

To address some of these questions, we prospectively analysed the anti-SARS-CoV-2 spike (S) protein immunoglobulin G (IgG) titres over multiple time-points (TPs), and monitored clinical outcomes [asymptomatic infections and coronavirus disease 2019 (COVID-19)], after two doses of 30 µg 3 weeks apart of BNT162b2 in 182 consecutive patients with different malignancies [chronic myeloid leukaemia (CML), lymphocytic leukemia].

1. Walsh EE, French RW, Faley AR, Kitchin N, Abdulon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–50.
2. Barriere J, Chamorey E, Adjoutjah Z, Castelnau O, Mahamat A, Marco S, et al. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors. Ann Oncol. 2021;32(8):1053–5. https://doi.org/10.1016/j.annonc.2021.04.019
3. Agha ME, Blake M, Chilleo C, Wells A, Haidar G. Suboptimal response to coronavirus disease 2019 messenger RNA vaccines in patients with hematologic malignancies: a need for vigilance in the postmasking era. Open Forum Infect Dis. 2021;8(7):ofab353. https://doi.org/10.1093/ofid/ofab353
4. Herishanu Y, Arivi I, Aharon S, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165–73. https://doi.org/10.1182/blood.2021011568
5. Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325(21):2204–6.
6. Ou MT, Boyarsky BJ, Motter JD, Greenberg RS, Teles AT, Ruddly JA, et al. Safety and reactogenicity of 2 doses of SARS-CoV-2 vaccination in solid organ transplant recipients. Transplantation. 2021. https://doi.org/10.1097/TP.0000000000003780. Epub ahead of print. PMID: 33859151.
7. Redjoul R, Le Bouter A, Beckerich F, Fourati S, Maury S. Antibody response after second BNT162b2 dose in allogeneic HSCT recipients. Lancet. 2021;398(10297):298–9.
8. Ram R, Hagan D, Kikozashvilli N, Freund T, Amit O, Bar-On Y, et al. Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy—a single-center prospective cohort study. Transplant Cell Ther. 2021;S2666-6367(21)01027-7. https://doi.org/10.1016/j.jtct.2021.06.024. Epub ahead of print. PMID: 34214738; PMCID: PMC8242200.
9. Dhakal B, Abedin SM, Fenske TS, Chhabra S, Ledeboer N, Hari P, et al. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR-T cell therapy. Blood. 2021;Epub ahead of print. PMID: 34393901; PMCID: PMC8242200.
10. Dan JM, Mateus J, Kato YU, Hastei KM, Yu ED, Falili CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063.
Table I. Geometric mean concentrations of anti-SARS-CoV-2 IgG and response rates according to seven different cohorts of haematological malignancy patients compared to a control cohort at 5 and 12 weeks after BNT162b2 vaccination.

| Patients' number (dropouts versus TP2) | TP2: Fifth week from the first dose of BNT162b2 vaccine | TP3: 12th week from the first dose of BNT162b2 vaccine |
|----------------------------------------|--------------------------------------------------------|-----------------------------------------------------|
| Control cohort (aged >80 years) | First cohort CML on TKIs | Second cohort PV-ET on active therapy@ | Third cohort MM on PI-IMIDs therapy without anti-CD38 | Fourth cohort B-NHL with TI >3 months since last anti-CD20 | Fifth cohort MM on active therapy@ | Sixth cohort MM on anti-CD38 | Seventh cohort B-NHL with TI < 3 months since last anti-CD20 |
| GMG (95% CI), au/ml [P] | 353.3 (261.7–459.8) | 369.8 (225.0–558.7) | 217.9 (131.7–337.1) | 220.7 (122.4–386.9) | 132.7 (48.5–345.9) | 32.4 (11.3–92.0) | 25.4 (14.5–43.8) | 4.7 (4.0–5.8) |
| Responders at the cut-off value ≥ 15 au/ml, n (%) [P]° | 36 (100) | 20 (100)* | 30 (93.8) | 30 (93.8) | 15 (78.9) | 6 (60) | 10 (55-6) | 1 (2.0) |
| Responders at the cut-off value ≥ 80 au/ml, n (%) [P]° | 35 (97.2) | 19 (95) | 29 (90.6) | 23 (71.9) | 13 (68.4) | 4 (40) | 5 (27.8) | 0 (0) |

Correspondence
Table I. (Continued)

| Cohort                                      | Control cohort (aged >80 years) | First cohort CML on TKIs | Second cohort PV-EI on active therapy@ | Third cohort MM on PI-IMIDs therapy without anti-CD38 | Fourth cohort B-NHL with TI >3 months since last anti-CD20 | Fifth cohort MF on active therapy@ | Sixth cohort MM on anti-CD38 | Seventh cohort B-NHL with TI <3 months since last anti-CD20 |
|---------------------------------------------|---------------------------------|--------------------------|----------------------------------------|-------------------------------------------------------|----------------------------------------------------------------|----------------------------------|-----------------------------|---------------------------------------------------------------|
| Responders with putative protection at the ratio Co/S > 10, n (%) | 22 (78.6) [P = 0.716]          | 17 (85) [P = 1]          | 26 (81.3) [P = 0.259]                 | 20 (62.5) [P = 0.034]                                 | 9 (47.4) [P = 0.434]                       | 1 (11.9) [P = 0.001]^               | 2 (11.8) [P < 0.001]                   | 0 (0) [P < 0.001]                                                   |

Statistics: cohorts were compared using Fisher’s exact test for categorical data and the Mann–Whitney test for continuous variables. The geometric mean values were calculated as \( \exp \text{mean}([-\log_{10}\text{value}]) \). CIs for GMCs were calculated based on logarithm of titres. All \( P \) values were two-sided, and those < 0.05 were considered statistically significant. Analysis was performed using the Statistical Package for the Social Sciences (SPSS®, version 20; IBM Corp., Armonk, NY, USA).

au, artificial units; B-NHL, B-cell non-Hodgkin lymphoma; CI, confidence interval; CML, chronic myeloid leukaemia; ET, essential thrombocythaemia; GMC, geometric mean concentration; IgG, immunoglobulin G; IMIDs, immunomodulatory imide drugs; MM, multiple myeloma; PI, proteasome inhibitor; PV, polycythaemia vera; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; TI, time interval; TKIs, tyrosine kinase inhibitors; TP, time-point; MF, myelofibrosis; @ hydroxycarbamide, ruxolitinib, interferon α, anagrelide.

#Anti SARS-CoV-2 S1/S2 IgG determination was performed by the Liaison® SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Saluggia, Italy).11 This is a quantitative chemiluminescent immunoassay (CLIA), fully automated on the LIAISON XL platform, for the detection of IgG antibodies against the subunits S1 and S2 of SARS-CoV-2 Spike protein. The subunits S1 and S2 are responsible for binding and fusion of virus to host cell, respectively, and are both targets of neutralising antibodies. According to the manufacturers’ technical manual, the result of a Liaison SARS-CoV-2 S1/S2 IgG test is positive with a signal of ≥15 au/ml, equivocal between 12 and 15 au/ml and negative below 12 au/ml. The cut-off to discriminate positive and negative results was individuated on the basis of the 94.4% concordance between the Liaison IgG titre of 15 au/ml and the Plaque Reduction Neutralisation Test 90% (PRNT90) at 1:40 ratio. At a Liaison value of 80 au/ml a concordance of 100% with a 1:160 PRNT90 titre was observed.13

##Angiotensin-converting enzyme 2 (ACE2)-receptor-binding domain (RBD) Neutralising Assay (Dia.pro, Milan, Italy)12 was used at TP3 to detect neutralising antibodies (NAb)s in an isotype-independent manner using purified RBD and the host cell receptor ACE2. The test is a surrogate Virus Neutralising Test (sVNT), a method that mimics the virus–host interaction in an enzyme-linked immunosorbent assay platewell. The RBD-ACE2 interaction can be neutralised by specific NAb)s in patient sera. The calculation of inhibition and the quantitative measurement of NAb)s was performed according to the manufacturer's instructions. The results are interpreted as a ratio of the cut-off value (Co) and the sample OD450 nm/620 nm (S). A Co/S > 10 indicates an efficient immunisation and vaccination effectiveness.14

*No statistics were computed because responders were a constant.

**Death from lymphoma progression.

^One of the 10 patients with MF was not tested by ACE2-RBD Neutralising Assay because of sample unavailability.
n = 20; myeloproliferative neoplasms (MPN), n = 42; multiple myeloma (MM), n = 50; and B-cell non-Hodgkin lymphoma (B-NHL), n = 70] enrolled in an observational monocentric study. At vaccination, patients with CML, MPN and MM were on active treatment, while patients with B-NHL were on active therapy or within 6 months from the end of such therapy, all negative for a previous SARS-CoV-2 infection. The present report is the first one focussing on 12-week serological kinetics in different blood cancers. The present study was controlled by a cohort of 36 subjects aged >80 years without cancer and approved by the Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Central Ethical Committee of Regione Lazio in January 2021 (Prot. N-1463/21). Anti-S IgG titres were measured before the first dose (TP0), after 3 weeks on the occasion of the second dose (TP1), and after 5 (TP2) and 12 weeks (TP3) from the first dose by a chemiluminescent immunoassay (Diasorin, Saluggia, Italy). At TP3, neutralising antibodies were also evaluated by angiotensin-converting enzyme 2 (ACE2)-receptor binding domain (RBD) neutralisation assay (Dia.pro, Milan, Italy). Nasopharyngeal swabs for real-time polymerase chain reaction testing (Anatolia geneworks, Istanbul, Turkey) were taken at TP0, TP1, and in all the cases of clinical suspicion of COVID-19 or hospital access. The 182 patients and 36 controls characteristics and immunogenicity data at TP2 have already been published for the MM, CML and MPN subsets and are unpublished for B-NHL. Among the patients with B-NHL the median age was 68 years, with a slight prevalence of indolent lymphomas and patients on induction or maintenance systemic therapy. Based on the prediction of serological response to BNT162b2 at TP2, cohorts of MM, MPN and B-NHL were split
Correspondence

according to treatment with or without an anti-cluster of differentiation (CD)38 monoclonal antibody (moAb), diagnosis of myelofibrosis (MF) or polycythaemia vera (PV)/essential thrombocythaemia (ET), and time interval (TI) since last anti-CD20 moAb administration to vaccination within or beyond 3 months respectively. In this way, seven different cohorts were identified (Table I; Fig 1A), the first four responsive, the last three weakly responsive or not responsive at all to vaccination: CML on tyrosine kinase inhibitors (first cohort, \( n = 20 \)), PV and ET on active therapy grouped together (second cohort, \( n = 32 \)), MM on proteasome inhibitors and/or immunomodulatory imide drugs without anti-CD38 moAb (third cohort, \( n = 32 \)), B-NHL with TI >3 months since last anti-CD20 administration (fourth cohort, \( n = 19 \)), MF on active therapy (fifth cohort, \( n = 10 \)), MM on anti-CD38 moAb (sixth cohort, \( n = 18 \)), B-NHL with TI <3 months since last anti-CD20 administration (seventh cohort, \( n = 51 \)).

Focussing on TP3, two cohorts’ clusters may be observed (Table I; Fig 1A,B). The first cluster is represented by still largely serologically immunocompetent patients from the first four cohorts, in which the antibody decay kinetics varies by magnitude among the cohorts determining, regardless of the xenin reached, their close grouping alongside the control cohort, with an average loss of around 50–65% in terms of geometric mean concentrations (GMCs) of anti-S antibodies and putative seroprotection rates ranging from 50% to 85%. The second cluster is represented by heavily immunocompromised patients from the last three cohorts, who display flat kinetics, with seroprotection rates of around 0–10% at 12 weeks. Booster vaccinations will likely be required based on kinetics, although the most appropriate timing remains currently unknown and probably different depending on the membership in one or the other cluster. Longitudinal assessments of the two mRNA vaccines with and without prior SARS-CoV-2 infection using quantitative enzyme-linked immunosorbent assay (ELISA) of anti-RBD antibodies in the general population demonstrate that the titres wane with kinetics very similar to that seen after mild natural infection, resulting in an average of ~90% loss within 90 days. The discrepancy between these results and ours at 3 months could be related to the different assays used.

The titres of anti-S IgG and neutralising antibodies were significantly correlated in the whole study population (Spearman’s \( \rho = 0.85, P < 0.001 \); Fig 1C), with protection rates calculated at the cut-off value \( \geq 80 \) artificial units/ml (au/ml) for the anti-SARS-CoV-2 S1/S2 IgG assay (DiaSorin) and at the ratio Co/S >10 for the ACE2-RBD neutralising assay (Dia.pro) rather superimposable (Table I). This reproducibility of results between the two assays we used appears comforting for the purposes of the widest possible serological monitoring of these patients. The choice of the reference cut-off appears fundamental to discriminate patients hypothetically protected by adequate levels of putatively neutralising antibodies.

An asymptomatic SARS-CoV-2 infection was documented in two patients belonging to the third and seventh cohort when nasopharyngeal swabs were taken as surveillance before their hospital access on 9 July 2021. Genomes were analysed by next-generation sequencing with the Illumina COVIDSeq Test on a Nextseq 500, Illumina Inc. (San Diego, CA, USA). The lineage assigned by the Phylogenetic Assignment of Named Global Outbreak Lineages (PANGOLIN) web-based software was B.1.617.2 in both cases, with genome coverage of 92.48% and 91.42% respectively (Global Initiative on Sharing All Influenza Dataset ID: EPI_ISL_2983378 and EPI_ISL_2983377). No cases of COVID-19 were reported. To date, the contagion has remained low despite the wide viral circulation due to the Delta variant. It would be important to correlate the humoral immunity data with those of cellular immunity, in order to verify whether also serologically unresponsive patients develop an efficient post-vaccine adaptive immunity.

Acknowledgments

Special thanks to all the I. F. O.-COVID-19-Team: Ilaria Cavallo, Andrea Cazzani, Ilaria Celesti, Ludovica Ciuﬀredia, Giovanna D’austo, Francesca De Nicola, Martina Diana, Sara Donzelli, Antonio Federico, Fulvia Fraticelli, Lorenzo Furzi, Frauke Inger Karen Goeman, Alessia Lauretti, Francesca Maione, Alice Massacci, Arianna Mastrofrancesco, Carla Mottini, Francisco Obregon, Matteo Pallocca, Silvia Paluzzi, Sara Petrolo, Grazia Prignano, Valentina Ricca, Serena Salvo, Eleonora Sperandio, Elisabetta Trento.

Author contributions

Francesco Marchesi had a major contribution in constructing the dataset, interpreting the data and writing the manuscript. Fulvia Pimpinelli implemented the laboratory platforms to carry out the study, performed all serological and molecular tests, validated, and interpreted the results and signed the reports. Eleonora Sperandio carried out the statistical analysis. Elena Papa and Paolo Falucci collected the signed informed consents and clinical data for the construction of the dataset. Martina Pontone contributed by performing serological and molecular tests. Simona di Martino and Luisa de Latouliere were in charge of preservation of serum at the biological bank. Giulia Orlandi performed the next-generation sequencing. Aldo Morrone conceived and developed the study. Gennaro Ciliberto conceived and developed the study. Andrea Mengarelli contributed to develop the study, construct the dataset, interpret the data, perform the statistical analysis and write the manuscript. All the authors read and approved the final manuscript.

Funding information

No special funds were used. Diagnostic tests were part of the diagnostic routine.
Conflict of interest

The authors have no conflicts of interest to disclose.

Francesco Marchesi1 on behalf of I.F.O.-COVID-19-Team
1Haematology Unit, Department of Research and Clinical Oncology, IRCCS Regina Elena National Cancer Institute, 2Microbiology and Virology Unit, Dermatological Clinical and Research Department, IRCCS San Gallicano Institute, 3Biostatistics and Bioinformatics Unit, Virology Unit, Dermatological Clinical and Research Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy. E-mail: francesco.marchesi@ifo.gov.it

Eleonora Sperandio3
Simona di Martino4
Luisa de Latouliere5
Simona di Martino4
Giulia Orlandi6
Luisa de Latouliere5
Martina Pontone2
Paolo Falcucci1
Elena Papa1
Eleonora Sperandio3
Fulvia Pimpinelli2
Francesco Marchesi1

Keywords: severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), BNT162b2, haematological cancers

First published online 6 September 2021
doi: 10.1111/bjh.17821

References
1. Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, del Molino del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22:765–78. https://doi.org/10.1016/S1470-2045(21)00213-8.

2. Bird S, Panopoulou A, Shea RL, Tsui M, Saso R, Sud A, et al. Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. Lancet Haematol. 2021;Re:e389–e392. https://doi.org/10.1016/s2352-3026 (21)00110-1.

3. Harrington P, Doores KJ, Radia D, O’Reilly A, Lam H, Peow J, et al. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukemia. Br J Haematol. 2021 [Online ahead of print]. https://doi.org/10.1111/bjh.17568.

4. Harrington P, de Lavallade H, Doores KJ, O’Reilly A, Peow J, Graham C, et al. Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralizing antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. Leukemia. 2021 [Online ahead of print]. https://doi.org/10.1038/s41375-021-01300-7.

5. Herishana Y, Avivi I, Aharon A, Shefer G, Levi S, Brunstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165–73. https://doi.org/10.1182/blood.202111568.

6. Roeker LE, Knorr DA, Thompson MC, Nivar M, Lebowitz S, Peters N, et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia. 2021 [Online ahead of print]. https://doi.org/10.1038/s41375-021-01270-w.

7. Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, et al. Fifth-week-immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single Institution. J Hematol Oncol. 2021;14:81. https://doi.org/10.1186/s13045-021-01090-6.

8. Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, et al. Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia. J Hematol Oncol. 2021;14:119. https://doi.org/10.1186/s13045-021-01130-1.

9. Van Oekelen O, Gleason CR, Agee S, Srivastava K, Beach KF, Aleman A, et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccine in patients with multiple myeloma. Cancer Cell. 2021;39:1028–30. https://doi.org/10.1016/j.ccell.2021.06.014.

10. Ghione P, Gu JJ, Attwood K, Torka P, Goel S, Sundaram S, et al. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell directed therapies. Blood. 2021 [Online ahead of print]. https://doi.org/10.1182/blood.2021012445.

11. Diasorin (Saluggia, Italy). Diasorin’s LAION® SARS-CoV-2 diagnostic solutions. 2021 [cited 2021 July 28]. Available from: https://www.diasorin.com/en/immunodiagnostic-solutions/clinical-areas/infectious-diseases/covid-19.

12. Dia.pro (Milan, Italy). COVID-19 – ELISA. 2021 [cited 2021 July 28]. Available from: https://www.dia.pro.it/products/ace2-rbd-neutralization-assay-elisa.

13. Anatolia geneworks, (Istanbul, Turkey). Novel coronavirus (2019-nCoV) diagnostic kits. 2021 [cited 2021 July 28]. Available from: http://www.anatoliageneworks.com/en/kits/novel-coronavirus-2019-ncov-detection-kits.

14. Ibarrondo FJ, Hofmann C, Fulcher JA, Goodman-Meza D, Mu W, Hauser MA, et al. Primary, recall, and decay kinetics of SARS-CoV-2 vaccine antibody responses. ACS Nano. 2021;15:11180–91. https://doi.org/10.1021/acsnano.1c03972.

15. Illumina Inc. (San Diego, CA, USA). Illumina COVIDSeq test. 2021 [cited 2021 July 28]. Available from: https://emea.illumina.com/products/br-by-type/ivd-products/covidseq.html

© 2021 British Society for Haematology and John Wiley & Sons Ltd
British Journal of Haematology, 2022, 196, 360–367